Glutamate Neonatal Excitotoxicity Modifies VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 Protein Expression Profiles During Postnatal Development of the Cerebral Cortex and Hippocampus of Male Rats
- 29 July 2017
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 63 (1) , 17-27
Abstract
Vascular endothelial growth factor (VEGF) exerts both neuroprotective and proinflammatory effects in the brain, depending on the VEGF (A–E) and VEGF receptor (VEGFR1–3) types involved. Neonatal monosodium glutamate (MSG) treatment triggers an excitotoxic degenerative process associated with several neuropathological conditions, and VEGF messenger RNA (mRNA) expression is increased at postnatal day (PD) 14 in rat hippocampus (Hp) following the treatment. The aim of this work was to establish the changes in immunoreactivity to VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 proteins induced by neonatal MSG treatment (4 g/kg, subcutaneous, at PD1, 3, 5 and 7) in the cerebral motor cortex (CMC) and Hp. Samples collected from PD2 to PD60 from control and MSG-treated male Wistar rats were assessed by western blotting for each protein. Considering that immunoreactivity measured by western blotting is related to the protein expression level, we found that each protein in each cerebral region has a specific expression profile throughout the studied ages, and all profiles were differentially modified by MSG. Specifically, neonatal MSG treatment significantly increased the immunoreactivity to the following: (1) VEGF-A at PD8–PD10 in the CMC and at PD6–PD8 in the Hp; (2) VEGF-B at PD2, PD6 and PD10 in the CMC and at PD8–PD9 in the Hp; and (3) VEGFR-2 at PD6–PD8 in the CMC and at PD21–PD60 in the Hp. Also, MSG significantly reduced the immunoreactivity to the following: (1) VEGF-B at PD8–PD9 and PD45–PD60 in the CMC; and (2) VEGFR-1 at PD4–PD6 and PD14–PD21 in the CMC and at PD4, PD9–PD10 and PD60 in the Hp. Our results indicate that VEGF-mediated signalling is involved in the excitotoxic process triggered by neonatal MSG treatment and should be further characterized.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (177594, Scholarship #510027)
- Universitario of Guadalajara (P3E2013-2017)
This publication has 61 references indexed in Scilit:
- Expression of VEGF and Flk-1 and Flt-1 Receptors during Blood-Brain Barrier (BBB) Impairment Following Phoneutria nigriventer Spider Venom ExposureToxins, 2013
- Cellular and molecular mechanisms involved in the neuroprotective effects of VEGF on motoneuronsFrontiers in Cellular Neuroscience, 2013
- Signal Transduction by Vascular Endothelial Growth Factor ReceptorsCold Spring Harbor Perspectives in Medicine, 2012
- Complicated life, complicated VEGF-BTrends in Molecular Medicine, 2012
- Delayed Administration of VEGF Rescues Spinal Motor Neurons from Death with a Short Effective Time Frame in Excitotoxic Experimental Models in VivoASN Neuro, 2012
- Role of vascular endothelial growth factor in adult hippocampal neurogenesis: Implications for the pathophysiology and treatment of depressionBehavioural Brain Research, 2012
- Neuronal FLT1 receptor and its selective ligand VEGF‐B protect against retrograde degeneration of sensory neuronsThe FASEB Journal, 2011
- Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injuryExperimental Neurology, 2008
- Biology of vascular endothelial growth factorsFEBS Letters, 2006
- Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administrationDevelopmental Biology, 2006